Pharmacotherapeutic Consequences of Recent Advances in Hemodialysis Therapy

Drukker W . Hemodialysis: A historical review. In: Maher J , eds. Replacement of renal function by dialysis. 3rd ed. Dordrecht, Holland: Kluwer Academic Publishers, 1989: 20–86.

US Renal Data Systems, USRDS 1993 annual data report. The National Institutes of Health, Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, March 1993.

Maher J . Pharmacological considerations for renal failure and dialysis. In: Maher J , eds. Replacement of renal function by dialysis. 3rd ed. Dordrecht, Holland: Kluwer Academic Publishers, 1989: 1018–76.

Matzke GR Millikin SP . Influence of renal function and dialysis on drug disposition. In: Evans WE Schentag JJ Jusko WJ , eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992; 8–6–8–49.

Hoenich NA Woffindin C Ward MK . Dialysers. In: Maher J , eds. Replacement of renal function by dialysis. 3rd ed. Dordrecht, Holland: Kluwer Academic Publishers, 1989: 144–88.

Sigdell JE . Operating characteristics of hollow-fiber dialyzers. In: Nissenson AR Fine RN Gentile DE , eds. Clinical dialysis. 2nd ed. Norwalk, CT: Appleton & Lange, 1990; 97–117.

Rovin BH . Dosage adjustments of drugs in renal failure. In: Dunagan WC Ridner ML , eds. Manual of medical therapeutics. 26th ed. Boston: Little, Brown and Company, 1989: 520–3.

Bennett WM Aronoff GR Golper TA Morrison G Singer I Brater DC . Drug prescribing in renal failure: dosing guidelines for adults. 2nd ed. Philadelphia: American College of Physicians, 1991: 54–5.

Weiss LG Cars O Danielson BG Grahnen A Wikstrom B . Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 1988: 30 (5):282–6.

Toffelmire EB Reymond JPH Broudar R Hassanzadeh MK Schoenfeld P Gambertoglio J . Dialysis clearance in high flux hemodialysis with reuse using ceftazidime as the model drug (abstract). Clin Pharmacol Ther 1989; 45: 160.

Herrero A Alarco FR Garcia-Diez JM Mahiques E Dominqo JV . Pharmacokinetics of netilmicin during hemodialysis: Comparison of four artificial kidneys. Int J Clin Pharmacol Ther Toxicol 1988; 26: 605–9.

Bastani B Spyker DA Minocha A Cummings R Westervelt FB . In vivo comparison of three different hemodialysis membranes for vancomycin clearance: Cuprophan, cellulose acetate, and polyacrylonitrile. Dial Transplant 1988; 17: 527–43.

Lanese DM Alfrey PS Molitoris BA Gal J . Markedly increased clearance of vancomycin during hemodialysis using polysulfone dialyzers. Kidney Int 1989; 35: 1409–13.

Pollard TA Lampasona V Mullins RE Hooks MA Wheaton R . Vancomycin redistribution: Dosing recommendations following high flux hemodialysis. Kidney Int 1994; 45: 232–7.

Minakata T Fukazawa A Ikeda Y . Comparison of vancomycin clearance during hemodialysis between high flux and conventional membranes (abstract). J Am Soc Nephrol 1991; 2: 339.

Torras J Cao C Rivas MC Cano M Fernandez E Mantoliu J . Pharmacokinetics of patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991; 36: 35–41.

Lowrie EG Laird NM Parker TF Sargent JA . Effect of the hemodialysis prescription on patient morbidity. N Engl J Med 1981; 12: 1176–81.

Gotch FA . Kinetic modeling in hemodialysis. In: Nissenson AR Fine RN Gentile DE , eds. Clinical dialysis. 2nd ed. Norwalk, CT: Appleton & Lange 1990: 366–90.

Held J Levin NW Bovbjerg RR Mark JD Pauly MV Diamond LH . Mortality and duration of hemodialysis treatment. JAMA 1991; 265: 871–5.

Gotch FA Uehlinger DE . Mortality rate in U.S. dialysis patients. Dialysis Transplant 1991; 20 (5):255–7.

Hornberger JC Chernew M Petersen J Garber AM . Multivariate analysis of mortality and hospital admissions with high-flux dialysis. J Am Soc Nephrol 1992; 3: 1227–37.

Keshaviah P Davis-Pollack R Luhring D Lee P . Practical guide to rapid high efficiency dialysis. 2nd ed. Minneapolis: Minneapolis Medical Research Foundation, 1989.

Matzke GR . Vancomycin. In: Evans WE Schentag JJ Jusko WJ , eds. Applied pharmacokinetics: Principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics 1992; 15–2–15–31.

Shusterman NH Feldman HI . Reuse of hemodialyser. In: Nissenson AR Fine RN , eds. Dialysis therapy. Philadelphia: Hanley & Belfus 1993; 133–8.

Eschbach JW Abdulhadi MH Browne JK Delano GB Downing MR Egrie JC . Recombinant human erythropoietin in anemic patients with end-stage renal disease: Results of a phase III, multicenter clinical trial. Ann Intern Med 1989; 111: 992–1000.

Marsh JT Brown WS Wolcott D Carr CR Harper R Schweitzer SV . RHUEPO treatment improves brain and cognitive function of anemic dialysis patients. Int Soc Nephrol 1991; 39: 155–63.

Buur T Lundberg M . Secondary effects of erythropoietin treatment on metabolism and dialysis efficiency in stable hemodialysis patients. Clin Nephrol 1990; 34: 230–5.

Barbhaiya RH Knupp CA Forgue ST Matzke GR Guay DRP Pittman KA . Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther 1990; 48: 268–76.

Halstenson CE Kelloway JS Affrime MB Lin CC Teal MA Shapiro BE Awni WM . Isepamicin disposition in subjects with various degrees of renal functions. Antimicrob Agents Chemother 1991; 35: 2382–7.